Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lumosa Therapeutics Co Ltd (6535) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8021
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lumosa Therapeutics Co Ltd (Lumosa Therapeutics) is a developer of drugs for the treatment of neurological and inflammatory diseases. The company’s pipeline products include LT-1001, an analgesic injection for severe pain relief; and LT-3001, a novel small molecule for acute ischemic stroke. Its activities comprise chemical development, translational research, preclinical, intellectual property, regulatory affairs, clinical development, project management and business development. Lumosa Therapeutics’s translational research services include disease model development, in vitro biassay development, acute toxicity pilot evaluation, bioanalytical method development, product stability analysis, compound purity analysis, and others. The company partners with biotech and pharmaceutical companies for product licensing, development and commercialization. Lumosa Therapeutics is headquartered in Taipei, Taiwan.

Lumosa Therapeutics Co Ltd (6535) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Lumosa Therapeutics Enters into Agreement with Camargo Pharma 10
Licensing Agreements 11
InteRx Biomedical Enters into Licensing Agreement with Lumosa Therapeutics 11
Equity Offering 12
Lumosa Therapeutics to Raise USD14.5 Million in Public Offering of Shares 12
Shundu Therapeutics Raises Funds through Private Placement 13
Lumosa Therapeutics Co Ltd – Key Competitors 14
Lumosa Therapeutics Co Ltd – Key Employees 15
Lumosa Therapeutics Co Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
03/14/2017: Lumosa’s LT1001 Approved in Taiwan 17
Product Approvals 18
Aug 28, 2017: Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain in the US 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumosa Therapeutics Enters into Agreement with Camargo Pharma 10
InteRx Biomedical Enters into Licensing Agreement with Lumosa Therapeutics 11
Lumosa Therapeutics to Raise USD14.5 Million in Public Offering of Shares 12
Shundu Therapeutics Raises Funds through Private Placement 13
Lumosa Therapeutics Co Ltd, Key Competitors 14
Lumosa Therapeutics Co Ltd, Key Employees 15

List of Figures
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TOMS Gruppen AS:企業の戦略的SWOT分析
    TOMS Gruppen AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • ATCC:製薬・医療:M&Aディール及び事業提携情報
    Summary ATCC is a nonprofit bioresource center and research organization that provides biological products, technical services and educational programs. The organization acquires, preserves, develops, authenticates, produces, and distributes standard reference microorganisms, cell lines and other ma …
  • Ridley USA Inc:企業の戦略的SWOT分析
    Ridley USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Ora Gold Ltd (THX):企業の財務・戦略的SWOT分析
    Summary Ora Gold Ltd (Ora Gold) is a mining and mineral exploration company. The company acquires, explores and develops lead, zinc, silver, nickel, graphite, copper, gold and uranium prospects in Western Australia and the Northern Territory. Its projects include Red Bore Copper-Gold Project, Garden …
  • Anglo American Plc:企業のM&A・事業提携・投資動向
    Anglo American Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anglo American Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • International Fibres Group Ltd:企業の戦略的SWOT分析
    International Fibres Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Westlake Chemical Corp (WLK):企業の財務・戦略的SWOT分析
    Summary Westlake Chemical Corp (Westlake Chemical) is a chemical company that manufactures and distributes petrochemicals, plastics and building products. The company offers products such as olefins, vinyls, styrene, polyethylene, epolene polymers, and others. It manufactures two primary petrochemic …
  • General Cable Corp (BGC):企業の戦略的SWOT分析
    General Cable Corp (BGC) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Alpine Immune Sciences Inc (NVLS):企業の財務・戦略的SWOT分析
    Summary Alpine Immune Sciences Inc (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company that discovering and developing innovative, protein-based immunotherapies, immune synapse to treat cancer and autoimmune and inflammatory diseases. The has two products in the clinic for infla …
  • Volt Information Sciences Inc (VOLT):企業の財務・戦略的SWOT分析
    Volt Information Sciences Inc (VOLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Buck Institute for Research on Aging:製薬・医療:M&Aディール及び事業提携情報
    Summary Buck Institute for Research on Aging (Buck Institute) is a biomedical institute that conducts research on aging and chronic disease. The institute concentrates on understanding the connection between aging and chronic disease. It carries out research and develops treatments in the therapeuti …
  • CIRCOR International, Inc. (CIR):石油・ガス:M&Aディール及び事業提携情報
    Summary CIRCOR International Inc (CIRCOR) is an industrial equipment company that designs, manufactures, and markets flow control solutions and engineered products and sub-systems. Its product offerings include integrated flow control solutions, high pressure pneumatic systems, valves, actuation, sw …
  • Boston Children’s Hospital:企業の戦略的SWOT分析
    Boston Children's Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Riverbed Technology Inc:企業の戦略的SWOT分析
    Riverbed Technology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • GeNeuro SA (GNRO):企業の財務・戦略的SWOT分析
    Summary GeNeuro SA (GeNeuro) operates as a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develo …
  • SeaWorld Entertainment, Inc.:企業の戦略・SWOT・財務情報
    SeaWorld Entertainment, Inc. - Strategy, SWOT and Corporate Finance Report Summary SeaWorld Entertainment, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Lamperd Less Lethal Inc.:企業の戦略・SWOT・財務情報
    Lamperd Less Lethal Inc. - Strategy, SWOT and Corporate Finance Report Summary Lamperd Less Lethal Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • RCL Foods Ltd. (RCL):企業の財務・戦略的SWOT分析
    RCL Foods Ltd. (RCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • De La Rue Plc
    De La Rue Plc - Strategy, SWOT and Corporate Finance Report Summary De La Rue Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • BioLineRx Ltd (BLRX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its’s product pipeline includes BL-8040, a short peptide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆